LASCCO, a biomedical-technology company, and Abionic, a nanotechnology company, both based at the Biopôle of Lausanne, entered into a licensing agreement with Fapon Biotech, a global leading life sciences company, based in Dongguan (China) for the use of the pancreatic stone protein (PSP) biomarker for sepsis diagnosis in China.
Abionic has been LASCCO’s partner since 2015 for the development and commercialization of PSP on Abionic’s abioSCOPE® device, which has been commercially deployed in 20+ countries since 2022 and is already widely used to diagnose ICU patients in several European hospitals.
Under this agreement, Fapon will engage in the development and commercialization of PSP on its chemiluminescent immunoassay (CLIA) analyzer within the Chinese market. This strategic partnership will usher in a significant breakthrough in the medical field, removing barriers to early sepsis diagnosis.
VISCHER advised LASCCO on all legal issues related to the license agreement. The team was led by partner Christian Wyss (pictured) with Pauline Pfirter (senior associate) and Luzius Zumstein (managing associate, all corporate / M&A) and also includes Lukas Züst (counsel, Head of China Desk), and Qinqin Yao (associate, China Desk).